摘要
目的观察拉米夫定治疗活动性肝硬化患者的疗效。方法随机选择活动性肝硬化患者57例,其中29例作为观察组,对照组28例使用常规综合治疗。观察组在此基础上加用拉米夫定100mg/日,口服,治疗8个月。观察临床症状和肝功能、Child-Pugh积分、肝纤维化指标以及HBV DNA、e系统血清转换等。结果治疗8个月时,临床症状改善、HBV DNA阴转、肝功能改善,以及有无合并症的出现,观察组均明显优于对照组。结论拉米夫定治疗活动性肝硬化,能抑制病毒复制,改善肝功能,稳定病情,改善预后。
Objective To observe the effectiveness of lamivudine on HBV related active cirrhosis. Methods Serum HBV DNA,ALT,ALB,TBil,PTA and Child-Pugh score were observed in 57 patients with active cirrhosis, out of which 28 cases as control group were given routine therapy for 8 months and the 29 cases were given lamivudine 100mg orally daily for 8 months at the base of conventional treatment. Results The clinical symptom and the life quality improved, and the Child-Pugh score declined. The negative rate of serum HBV DNA and liver function in lamivudine group were obvious better than in control group at the end of 8 month treatment. Conclusion lamividine can inhibit HBVDNA in patients with active cirrhosis, therefore improve liver function, stabilize patient＇ s condition and improve prognosis.
出处
《实用肝脏病杂志》
CAS
2005年第6期331-333,共3页
Journal of Practical Hepatology
